Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 954

1.

The importance of diagnostic cytogenetics on outcome in AML: analysis of 1,612 patients entered into the MRC AML 10 trial. The Medical Research Council Adult and Children's Leukaemia Working Parties.

Grimwade D, Walker H, Oliver F, Wheatley K, Harrison C, Harrison G, Rees J, Hann I, Stevens R, Burnett A, Goldstone A.

Blood. 1998 Oct 1;92(7):2322-33.

2.

Influence of cytogenetic abnormalities on outcome after allogeneic bone marrow transplantation for acute myeloid leukemia in first complete remission.

Chalandon Y, Barnett MJ, Horsman DE, Conneally EA, Nantel SH, Nevill TJ, Nitta J, Shepherd JD, Sutherland HJ, Toze CL, Hogge DE.

Biol Blood Marrow Transplant. 2002;8(8):435-43.

PMID:
12234169
3.

Pretreatment cytogenetic abnormalities are predictive of induction success, cumulative incidence of relapse, and overall survival in adult patients with de novo acute myeloid leukemia: results from Cancer and Leukemia Group B (CALGB 8461).

Byrd JC, Mrózek K, Dodge RK, Carroll AJ, Edwards CG, Arthur DC, Pettenati MJ, Patil SR, Rao KW, Watson MS, Koduru PR, Moore JO, Stone RM, Mayer RJ, Feldman EJ, Davey FR, Schiffer CA, Larson RA, Bloomfield CD; Cancer and Leukemia Group B (CALGB 8461).

Blood. 2002 Dec 15;100(13):4325-36. Epub 2002 Aug 1.

4.

The influence of age on prognosis of de novo acute myeloid leukemia differs according to cytogenetic subgroups.

Schoch C, Kern W, Schnittger S, Büchner T, Hiddemann W, Haferlach T.

Haematologica. 2004 Sep;89(9):1082-90.

5.

Karyotypic analysis predicts outcome of preremission and postremission therapy in adult acute myeloid leukemia: a Southwest Oncology Group/Eastern Cooperative Oncology Group Study.

Slovak ML, Kopecky KJ, Cassileth PA, Harrington DH, Theil KS, Mohamed A, Paietta E, Willman CL, Head DR, Rowe JM, Forman SJ, Appelbaum FR.

Blood. 2000 Dec 15;96(13):4075-83.

6.

Frequency of prolonged remission duration after high-dose cytarabine intensification in acute myeloid leukemia varies by cytogenetic subtype.

Bloomfield CD, Lawrence D, Byrd JC, Carroll A, Pettenati MJ, Tantravahi R, Patil SR, Davey FR, Berg DT, Schiffer CA, Arthur DC, Mayer RJ.

Cancer Res. 1998 Sep 15;58(18):4173-9.

7.
8.

A new prognostic score for patients with acute myeloid leukemia based on cytogenetics and early blast clearance in trials of the German AML Cooperative Group.

Haferlach T, Kern W, Schoch C, Schnittger S, Sauerland MC, Heinecke A, Büchner T, Hiddemann W; German AML Cooperative Group.

Haematologica. 2004 Apr;89(4):408-18.

9.

Correlation between CD34 expression and chromosomal abnormalities but not clinical outcome in acute myeloid leukemia.

Fruchart C, Lenormand B, Bastard C, Boulet D, Lesesve JF, Callat MP, Stamatoullas A, Monconduit M, Tilly H.

Am J Hematol. 1996 Nov;53(3):175-80.

10.

The prognostic value of cytogenetics is reinforced by the kind of induction/consolidation therapy in influencing the outcome of acute myeloid leukemia--analysis of 848 patients.

Visani G, Bernasconi P, Boni M, Castoldi GL, Ciolli S, Clavio M, Cox MC, Cuneo A, Del Poeta G, Dini D, Falzetti D, Fanin R, Gobbi M, Isidori A, Leoni F, Liso V, Malagola M, Martinelli G, Mecucci C, Piccaluga PP, Petti MC, Rondelli R, Russo D, Sessarego M, Specchia G, Testoni N, Torelli G, Mandelli F, Tura S.

Leukemia. 2001 Jun;15(6):903-9. Review.

PMID:
11417475
11.

Prognostic value of karyotypic analysis in children and adults with high-risk acute lymphoblastic leukemia included in the PETHEMA ALL-93 trial.

Ribera JM, Ortega JJ, Oriol A, Granada I, Hernández-Rivas JM, Parody R, Bethencourt C, Rivas C, Bastida P, del Potro E, González-Valentín ME, Moreno MJ, Besalduch J, Fernández-Calvo J, Tormo M, Arias J, Molinés A, Sanz MA, Maldonado J, Millá F, Feliu E, San Miguel JF; PETHEMA Group, Spanish Society of Hematology.

Haematologica. 2002 Feb;87(2):154-66.

13.

Association of specific cytogenetic aberrations with mdr1 gene expression in adult myeloid leukemia and its implication in treatment outcome.

Schaich M, Harbich-Brutscher E, Pascheberg U, Mohr B, Soucek S, Ehninger G, Illmer T.

Haematologica. 2002 May;87(5):455-64.

14.

A systematic overview of chemotherapy effects in acute myeloid leukaemia.

Kimby E, Nygren P, Glimelius B; SBU-group. Swedish Council of Technology Assessment in Health Care.

Acta Oncol. 2001;40(2-3):231-52. Review.

PMID:
11441935
15.

Is secondary leukemia an independent poor prognostic factor in acute myeloid leukemia?

Larson RA.

Best Pract Res Clin Haematol. 2007 Mar;20(1):29-37. Review.

PMID:
17336252
16.

Prognosis of acute myeloid leukemia patients up to 60 years of age exhibiting trisomy 8 within a non-complex karyotype: individual patient data-based meta-analysis of the German Acute Myeloid Leukemia Intergroup.

Schaich M, Schlenk RF, Al-Ali HK, Döhner H, Ganser A, Heil G, Illmer T, Krahl R, Krauter J, Sauerland C, Büchner T, Ehninger G.

Haematologica. 2007 Jun;92(6):763-70.

17.

Del (9q) AML: clinical and cytological characteristics and prognostic implications.

Peniket A, Wainscoat J, Side L, Daly S, Kusec R, Buck G, Wheatley K, Walker H, Chatters S, Harrison C, Boultwood J, Goldstone A, Burnett A.

Br J Haematol. 2005 Apr;129(2):210-20.

PMID:
15813849
18.

A white blood cell index as the main prognostic factor in t(8;21) acute myeloid leukemia (AML): a survey of 161 cases from the French AML Intergroup.

Nguyen S, Leblanc T, Fenaux P, Witz F, Blaise D, Pigneux A, Thomas X, Rigal-Huguet F, Lioure B, Auvrignon A, Fière D, Reiffers J, Castaigne S, Leverger G, Harousseau JL, Socié G, Dombret H.

Blood. 2002 May 15;99(10):3517-23.

19.

Clinical, molecular, and prognostic significance of WHO type inv(3)(q21q26.2)/t(3;3)(q21;q26.2) and various other 3q abnormalities in acute myeloid leukemia.

Lugthart S, Gröschel S, Beverloo HB, Kayser S, Valk PJ, van Zelderen-Bhola SL, Jan Ossenkoppele G, Vellenga E, van den Berg-de Ruiter E, Schanz U, Verhoef G, Vandenberghe P, Ferrant A, Köhne CH, Pfreundschuh M, Horst HA, Koller E, von Lilienfeld-Toal M, Bentz M, Ganser A, Schlegelberger B, Jotterand M, Krauter J, Pabst T, Theobald M, Schlenk RF, Delwel R, Döhner K, Löwenberg B, Döhner H.

J Clin Oncol. 2010 Aug 20;28(24):3890-8. doi: 10.1200/JCO.2010.29.2771. Epub 2010 Jul 26.

PMID:
20660833
20.

Prognostic impact of specific chromosomal aberrations in a large group of pediatric patients with acute myeloid leukemia treated uniformly according to trial AML-BFM 98.

von Neuhoff C, Reinhardt D, Sander A, Zimmermann M, Bradtke J, Betts DR, Zemanova Z, Stary J, Bourquin JP, Haas OA, Dworzak MN, Creutzig U.

J Clin Oncol. 2010 Jun 1;28(16):2682-9. doi: 10.1200/JCO.2009.25.6321. Epub 2010 May 3.

PMID:
20439630

Supplemental Content

Support Center